E

Essential Pharma

Specialty pharma acquiring legacy, at-risk drugs

Associate Director - Business Development

Full-TimeUpdated on 10/23/2026
No salary listed
Expert
Bachelor's, MBA
Egham, UK
HybridHybrid in Egham; the employer also notes office-based contracts and flexibility on work location when appropriate.
Finance & BankingInvestment Banking

About the job

Requirements
  • At least 5 years of relevant experience in mergers and acquisitions, investment banking, corporate development, or strategic finance, focused on the pharmaceutical or life sciences sector.
  • Demonstrated experience building and analyzing complex financial models and valuations.
  • Evidence of strategic investment analysis and business case development.
  • Experience in competitor analysis and designing competitive growth strategies.
  • Experience using secondary industry resources for pharmaceutical and scientific data.
  • Multinational experience, at minimum pan-European.
  • High numeracy and analytical skills, attention to detail, and strong Excel skills.
  • Ability to work with large datasets to extract insights.
  • Strong written and reporting skills.
  • Ability to conduct research and use databases to obtain information.
  • Ability to manage workflow expectations.
  • Ability to work collaboratively and effectively with a team.
  • Ability to adapt to high-speed change and work through complex issues.
  • Integrity and high ethical standards; accountability for actions.
Responsibilities
  • Drive technical, commercial, and financial evaluations and due diligence of new mergers and acquisitions, asset in-licensing, and organic growth opportunities.
  • Screen, identify, and evaluate potential assets or companies aligned with the company’s growth objectives.
  • Conduct product-market research, data analysis, and commercial assessment to build business cases.
  • Support commercial and financial due diligence.
  • Build detailed profit-and-loss and net-present-value valuation models, conduct sensitivity analysis, and develop structured offer proposals.
  • Maintain the business development and mergers-and-acquisitions pipeline.
  • Manage database resources to generate business insights and competitive intelligence, and keep stakeholders informed about new opportunities.
  • Use IQVIA, Evaluate, PharmaProjects, AlphaSense, and similar databases to generate research and development pipeline and commercial portfolio insights for target identification, selection, and business case development.
  • Design and conduct primary and secondary market research to assess targets and develop reports for senior management and due diligence.
  • Size and forecast in-licensing, acquisition, and lifecycle opportunities using commercial data and epidemiology; review published clinical literature and pricing information; and perform competitive landscape analysis.
  • Build business cases, including financial forecast scenarios in Microsoft Excel.
  • Lead commercial and financial due diligence, project-manage interactions with external advisors and consultants, and be responsible for outputs.
  • Collaborate with cross-functional teams to assess target value opportunities and inform business cases.
  • Track market activity, competitor mergers and acquisitions, and industry trends to inform corporate strategy.
  • Generate recommendations, and advise and support the vice president of mergers and acquisitions on in-licensing and acquisition targets.
  • Support preparation of investment thesis papers for internal stakeholders.
  • Maintain and refresh the mergers-and-acquisitions pipeline.
Desired Qualifications
  • A degree in a life science field, such as Medicine, Biochemistry, Biology, or Biomedical Sciences.
  • An MBA, Chartered Financial Analyst (CFA), Chartered Institute of Management Accountants (CIMA), or similar qualification.
  • Creative thinking in generating financial models.
  • An inquisitive, curious, and investigative mindset, with willingness to challenge and learn.

About the company

Essential Pharma buys mature, low-volume medicines that larger pharma companies divest to keep patients supplied. It acquires at-risk and legacy drugs across rare diseases, CNS, ophthalmology, and gastroenterology, then commercializes and distributes them across about 70 countries, managing complex transfers and licenses to prevent shortages. Its growth comes from strategic acquisitions and licensing deals, such as rights to Iopidine and Methergine and the Renaissance Pharma integration, plus development-stage assets like an immunotherapy for high-risk neuroblastoma. Led by CEO Emma Johnson since 2023, the company aims to expand its portfolio and global reach to sustain access to essential medicines when big firms shift focus.

Company Size

51-200

Company Stage

Growth Equity (Non-Venture Capital)

Total Funding

$990M

Headquarters

Egham, United Kingdom

Founded

2000

Get referred to Essential Pharma

See people who can refer or advise you

Benefits

  • Health Insurance
  • Life Insurance
  • Paid Sick Leave
  • Parental Leave
  • Paid Vacation
  • Flexible Work Hours
  • Performance Bonus

Growth & Insights and Company News

6 month growth

11%

1 year growth

11%

2 year growth

11%
GlobeNewswire
Jul 3rd, 2025
Essential Pharma appoints experienced pharmaceutical leaders Simon Ramsden and Rob Smith to leadership team

Egham, UK - 03 July 2025 - Essential Pharma ("Essential" or "the Company"), a global pharmaceutical company developing and delivering medicines for patients in niche populations, today announces the appointment of Simon Ramsden as Chief Financial Officer and Rob Smith as Chief Technology Officer, both with immediate effect.

GlobeNewswire
May 6th, 2025
Essential Pharma strengthens management team with appointment of Duncan Ferguson as Vice President, Commercial

Egham, UK - 6th May 2025 - Essential Pharma ("Essential" or "the Company"), a global pharmaceutical company developing and delivering medicines for patients in niche populations, today announces the appointment of Duncan Ferguson as Vice President, Commercial.

GlobeNewswire
Apr 30th, 2025
Essential Pharma strengthens Board with the appointment of Jonathan Arnold as Non-Executive Director

Egham, UK - 30 April 2025 - Essential Pharma ("Essential" or "the Company"), a global pharmaceutical company developing and delivering medicines for patients in niche populations, today announces the appointment of Jonathan Arnold as a Non-Executive Director, with immediate effect.

Insider Media
Dec 12th, 2024
Pharma group completes £741m recapitalisation to build portfolio of rare disease medicines

Following the transaction, Lee Morley, appointed as non-executive director to the board in 2023, will assume the role of chairman of Essential Pharma, succeeding Dr Patrick Vink.

Real Deals
Dec 12th, 2024
Gyrus Capital raises €600m for Essential Pharma

Gyrus Capital, based in Geneva, has successfully raised a €600 million single-asset continuation vehicle to extend its hold on Essential Pharma.